ArticleAdvances in rheumatology (London, England)2025
Prevalence of solid tumors and lymphoma in the Brazilian Sjögren's Disease Registry (BRAS): an important concern for clinical practice.
Article in Advances in rheumatology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
backgroundAbout 5–10% of patients with Sjögren’s Disease (SjD) will develop non-Hodgkin’s lymphoma, with a 16 to 44 increased risk compared to the general population. The relationship between SjD and other types of cancer is poorly described in the literature.
aimTo characterize patients with SjD from the Brazilian Sjögren’s Disease Registry (BRAS) who developed hematological and solid neoplasms, analyzing the organ primarily involved, subtypes, occurrence of metastatic disease, timing of diagnosis and correlation with demographic, serologic aspects, and labial salivary gland inflammation.
methodsAmong consecutive patients included in the Brazilian Sjögren’s Disease Registry (BRAS) and fulfilling the 2002 or 2016 classification criteria for SjD, those who developed neoplasia were retrospectively identified and categorized according to the National Cancer Institute (Ministry of Health, Brazil).
results1,010 patients were included; of them, 975 were women (96.5%), with an average age of 55.6 ± 13.6 years. Disease duration was 11.9 ± 7.9 years. We found that 114 out of 1,010 patients (11.3%) had cancer, with a higher prevalence in those over 55 years old (p < 0.001). The most prevalent malignancies were skin cancer [24/858 (2.7%)], breast cancer [27/1010 (2.6%)], lymphoma [15/1010 (1.5%)], and thyroid cancer [8/1010 (0.8%)]. Further, 0.9% of patients had more than one type of cancer. Cancer diagnosis followed SjD diagnosis in 66.7% of lymphoma cases, 53.6% of other malignancies, and 75.0% of skin cancer. The presence of cancer was associated with age (OR 1.04). In the case of skin cancer, the duration of SjD was an additional risk factor (OR 1.08). For thyroid cancer, inflammation of the labial minor salivary glands was identified as an associated risk factor (OR 10.1).
conclusionsOther types of cancer were more prevalent than lymphoma in our population of SjD patients. Breast neoplasia emerged as the most prevalent after skin cancer, and thyroid cancer was the second most prevalent solid neoplasia. Aging, disease duration and labial salivary gland inflammation were associated risk factors. Prospective cohort studies are essential for assessing other risk factors for cancer development in SjD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.